Abstract

Amir Monfaredan64010, Fakher Rahim64011, Gholamreza Tavoosidana64012, Mohammad Hossein Modarressi64013, Alaviyehsadat hosseininasab64014, Ali-Akbar Aghajani-Afrouzi64015, Mahdi Shafiee Sabet64016 and Elahe Motevaseli64017*

Leukemia, a type of cancer that affects the blood and bone marrow, is a complex and devastating disease with limited treatment options. Over the years, researchers have been exploring novel therapeutic approaches to improve patient outcomes. One emerging area of interest is the role of exosomes in leukemia. Exosomes are small extracellular vesicles secreted by various cell types, including cancer cells. They play a crucial role in intercellular communication by transferring bioactive molecules such as microRNAs (miR- NAs) between cells. Recent studies have highlighted the involvement of exosome miRNAs in leukemia progression, therapy resistance, and disease prognosis. Understanding the mechanisms underlying exosome-mediated miRNA transfer in leukemia may provide valuable insights into disease pathogenesis and potential therapeutic targets. Furthermore, exosomes can serve as non-invasive biomarkers for leukemia diagnosis and monitoring treatment response. Studies have demonstrated that high levels of galectin-3 are associated with worse clinical outcomes in patients with leukemia. Understanding the specific mechanisms by which galectin-3 contributes to leukemogenesis could provide valuable insights into novel therapeutic strategies for this devastating disease. We characterized the abundance of exosomes as a function of the number and distribution in the samples. 48 h post downregulation of the LGALS3 gene, we observed a 1.2-fold increase in the release of exosomes compared to the control.